Xiaofang Wang Selected Research

Xiaofang Wang Research Topics

Disease

45	Neoplasms (Cancer) 05/2024 - 01/2003
19	Inflammation (Inflammations) 11/2023 - 10/2008
19	Infections 10/2023 - 06/2010
15	Polycystic Kidney Diseases (Polycystic Kidney Disease) 05/2024 - 11/2003
14	Autosomal Dominant Polycystic Kidney (ADPKD) 05/2024 - 11/2003
11	Cysts 05/2024 - 11/2003
10	Breast Neoplasms (Breast Cancer) 01/2024 - 06/2017
7	Pre-Eclampsia (Preeclampsia) 02/2022 - 10/2015
7	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2003
6	Multiple Myeloma 05/2024 - 01/2011
6	Lung Neoplasms (Lung Cancer) 04/2024 - 01/2023
6	Fibrosis (Cirrhosis) 11/2023 - 11/2003
6	Pneumonia (Pneumonitis) 07/2022 - 01/2017
6	Cardiomegaly (Heart Hypertrophy) 01/2022 - 01/2018
6	COVID-19 11/2021 - 01/2020
6	Hypertrophy 01/2021 - 01/2015
5	Virus Diseases (Viral Diseases) 08/2023 - 01/2017
5	Body Weight (Weight, Body) 04/2023 - 11/2003
5	Malaria 01/2022 - 03/2011
5	Huntington Disease (Huntington's Disease) 01/2019 - 06/2008
4	Hypoxia (Hypoxemia) 12/2023 - 05/2010
4	Heart Failure 08/2023 - 01/2022
4	Myocardial Infarction 08/2023 - 12/2011
4	Leukemia 01/2023 - 12/2019
4	Cognitive Dysfunction 01/2023 - 06/2015
4	Disease Progression 01/2021 - 01/2010
4	Prostatic Neoplasms (Prostate Cancer) 01/2019 - 01/2014
4	Autosomal Recessive Polycystic Kidney (Polycystic Kidney Disease, Infantile, Type I) 02/2009 - 03/2002
3	Squamous Cell Carcinoma of Head and Neck 09/2023 - 01/2019
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 08/2023 - 01/2018
3	Wounds and Injuries (Trauma) 01/2023 - 11/2018
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2023 - 08/2009
3	Type 2 Diabetes Mellitus (MODY) 12/2022 - 05/2018
3	Triple Negative Breast Neoplasms 02/2022 - 06/2017
3	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 11/2018
3	Bronchiolitis 01/2022 - 01/2020
3	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 01/2015
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 10/2017
3	Malnutrition (Nutritional Deficiencies) 09/2021 - 01/2017
3	Human Influenza (Influenza) 01/2021 - 01/2019
3	Coinfection 01/2021 - 11/2011
3	Ovarian Neoplasms (Ovarian Cancer) 11/2020 - 09/2018
3	Necrosis 11/2019 - 03/2015
3	Pneumococcal Infections 01/2018 - 01/2017
2	Carcinogenesis 01/2024 - 01/2015
2	Adenocarcinoma of Lung 01/2024 - 11/2021
2	Hypophosphatemia 12/2023 - 08/2014

Drug/Important Bio-Agent (IBA)

37	Proteins (Proteins, Gene)FDA Link 09/2022 - 03/2002
17	CytokinesIBA 11/2023 - 10/2008
14	Biomarkers (Surrogate Marker)IBA 12/2023 - 09/2015
10	Long Noncoding RNAIBA 11/2021 - 06/2017
9	Antiviral Agents (Antivirals)IBA 08/2020 - 01/2017
8	RNA (Ribonucleic Acid)IBA 01/2024 - 04/2019
8	Therapeutic UsesIBA 11/2023 - 10/2008
8	Glucose (Dextrose)FDA LinkGeneric 01/2023 - 03/2015
8	EnzymesIBA 03/2019 - 01/2003
7	Messenger RNA (mRNA)IBA 01/2023 - 01/2010
7	Vasopressin Receptors (Arginine Vasopressin Receptor)IBA 10/2021 - 04/2005
7	Vasopressins (Vasopressin)IBA 10/2021 - 01/2005
7	CalciumIBA 10/2021 - 02/2009
6	DNA (Deoxyribonucleic Acid)IBA 01/2024 - 03/2017
6	Phosphotransferases (Kinase)IBA 01/2023 - 01/2016
6	VaccinesIBA 11/2021 - 06/2010
6	Angiotensin IIIBA 01/2021 - 10/2015
5	MicroRNAs (MicroRNA)IBA 09/2023 - 01/2017
5	1,2,4-trioxaneIBA 01/2021 - 03/2011
4	PoisonsIBA 04/2024 - 01/2023
4	AntigensIBA 01/2024 - 02/2018
4	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2023 - 03/2015
4	CateninsIBA 02/2022 - 08/2017
4	pevonedistatIBA 03/2019 - 01/2014
3	2- (2,6- dimethylmorpholin- 4- yl)- N- (5- (6- morpholin- 4- yl- 4- oxo- 4H- pyran- 2- yl)- 9H- thioxanthen- 2- yl)acetamideIBA 04/2024 - 01/2023
3	Type II DNA Topoisomerases (Topoisomerase II)IBA 04/2024 - 01/2023
3	Oxygen (Dioxygen)IBA 11/2023 - 01/2019
3	Hemoglobins (Hemoglobin)IBA 11/2023 - 05/2018
3	AntioxidantsIBA 10/2023 - 01/2017
3	LipidsIBA 08/2023 - 03/2015
3	Streptozocin (Streptozotocin)FDA Link 01/2023 - 01/2019
3	Alanine Transaminase (SGPT)IBA 01/2023 - 03/2015
3	InterferonsIBA 10/2022 - 01/2020
3	Immunoglobulin G (IgG)IBA 03/2022 - 06/2011
3	Antimalarials (Antimalarial Agents)IBA 01/2022 - 11/2016
3	artemisinin (artemisinine)IBA 01/2022 - 11/2016
3	Competitive Endogenous RNAIBA 11/2021 - 01/2019
3	Interleukin-6 (Interleukin 6)IBA 10/2020 - 01/2019
3	Peptides (Polypeptides)IBA 02/2020 - 02/2018
3	Tolvaptan FDA Link 01/2020 - 04/2005
3	Interferon Type IIBA 01/2020 - 01/2017
3	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2020 - 01/2016
3	Ligases (Synthetase)IBA 03/2019 - 01/2014
3	Small Interfering RNA (siRNA)IBA 03/2019 - 07/2015
3	polyglutamineIBA 11/2017 - 08/2009
3	AutoantibodiesIBA 01/2016 - 01/2013
2	TRPP Cation ChannelsIBA 05/2024 - 01/2017
2	Etoposide (VP 16)FDA LinkGeneric 01/2024 - 01/2023

Therapy/Procedure

33	Therapeutics 01/2024 - 11/2004
9	Radiotherapy 01/2023 - 06/2016
6	Immunotherapy 01/2024 - 10/2021
5	Mastectomy (Mammectomy) 01/2024 - 10/2017
2	Intramuscular Injections 04/2024 - 01/2020